New way to treat cancer.
Frezent’s biologics effectively kill both dividing and non-dividing cancer cells, by disrupting cancer metabolism. This strategy will potentially eliminate minimal residual disease and prevent cancer recurrence.
We set a high bar to deliver a true clinical value.
Ensure complete response
We eliminate dividing and non-dividing (dormant) cancer cells to eliminate minimal residual disease.
Design NextGen biologics with AI
We integrate AI tools to optimize Frezent’s antibodies for enhanced selectivity and strong safety profiles.
Treat residual disease early
We integrate our treatment with standard of care to attack dormant cancer cells immediately when they are formed and before they transform into recurrent cancer.
Improve patient survival by preventing cancer progression.
20 million
New cancer cases annually worldwide
50%
Estimated risk of disease progression and mortality
“We want to give cancer survivors the confidence that their cancer won’t return, and to bring them and their families peace of mind.”
-Dr. Natasha Shtraizent, PhD, Co-founder and CEO of Frezent
Our team and partners
A multidisciplinary team of founders with deep scientific expertise, supported by an advisory board of proven leaders across biotech, business, and oncology therapeutics.
We partner with leading hospitals and work with key opinion leaders in oncology.
Frezent is supported by SOSV, New York Ventures (Empire State Development) and funding from NSF-SBIR grant.
We have joined accelerator programs to catalyze our journey from bench toward clinic.
Join us
Reach out for partnerships, investment opportunities, or general inquiries.